Mohammad Iqbal, Iwan Cahyo Santosa Putra, Rizki Bunawan, Hanna Goenawan, Mohammad Rizki Akbar, Arief Sjamsulaksan Kartasasmita, Young Hoon Kim
{"title":"可溶性抑制致瘤性2作为接受永久性起搏器治疗的心动过缓患者早期心脏重构的生物标志物。","authors":"Mohammad Iqbal, Iwan Cahyo Santosa Putra, Rizki Bunawan, Hanna Goenawan, Mohammad Rizki Akbar, Arief Sjamsulaksan Kartasasmita, Young Hoon Kim","doi":"10.2144/fsoa-2023-0001","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between pacemaker parameters and pacemaker mode along with delta sST2 levels.</p><p><strong>Materials & methods: </strong>This prospective cohort study enrolled all symptomatic bradycardia patients aged >18 years with preserved ejection fraction who underwent permanent pacemaker (PPM) implantation.</p><p><strong>Results: </strong>A total of 49 patients were included in this study. The sST2 level (ng/ml) were significantly different between prior and 1 month following PPM implantation (23.4 ± 28.4 vs 39.9 ± 63.7; p = 0.001).</p><p><strong>Conclusion: </strong>The early cardiac remodeling has occurred within 1 month after PPM implantation as indicated by increasing delta sST2 level.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"9 1","pages":"FSO831"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051037/pdf/","citationCount":"0","resultStr":"{\"title\":\"The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy.\",\"authors\":\"Mohammad Iqbal, Iwan Cahyo Santosa Putra, Rizki Bunawan, Hanna Goenawan, Mohammad Rizki Akbar, Arief Sjamsulaksan Kartasasmita, Young Hoon Kim\",\"doi\":\"10.2144/fsoa-2023-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between pacemaker parameters and pacemaker mode along with delta sST2 levels.</p><p><strong>Materials & methods: </strong>This prospective cohort study enrolled all symptomatic bradycardia patients aged >18 years with preserved ejection fraction who underwent permanent pacemaker (PPM) implantation.</p><p><strong>Results: </strong>A total of 49 patients were included in this study. The sST2 level (ng/ml) were significantly different between prior and 1 month following PPM implantation (23.4 ± 28.4 vs 39.9 ± 63.7; p = 0.001).</p><p><strong>Conclusion: </strong>The early cardiac remodeling has occurred within 1 month after PPM implantation as indicated by increasing delta sST2 level.</p>\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":\"9 1\",\"pages\":\"FSO831\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051037/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2144/fsoa-2023-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2144/fsoa-2023-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评估植入前后1个月心脏重构生物标志物可溶性抑制致瘤性2 (sST2)水平和超声心动图参数值的差异;以及起搏器参数和起搏器模式之间的关系以及δ sST2水平。材料与方法:本前瞻性队列研究纳入了所有年龄>18岁、保留射血分数并接受永久性起搏器(PPM)植入的有症状的心动过缓患者。结果:本研究共纳入49例患者。sST2水平(ng/ml)在PPM植入前和植入后1个月差异有统计学意义(23.4±28.4 vs 39.9±63.7;p = 0.001)。结论:早期心脏重构发生在PPM植入后1个月内，表现为δ sST2水平升高。
The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy.
Aim: This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between pacemaker parameters and pacemaker mode along with delta sST2 levels.
Materials & methods: This prospective cohort study enrolled all symptomatic bradycardia patients aged >18 years with preserved ejection fraction who underwent permanent pacemaker (PPM) implantation.
Results: A total of 49 patients were included in this study. The sST2 level (ng/ml) were significantly different between prior and 1 month following PPM implantation (23.4 ± 28.4 vs 39.9 ± 63.7; p = 0.001).
Conclusion: The early cardiac remodeling has occurred within 1 month after PPM implantation as indicated by increasing delta sST2 level.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
